Artificial intelligence-driven digital pathology in urological cancers: current trends and future directions.

Inyoung Paik¹, Geongyu Lee¹, Joonho Lee¹, Tae-Yeong Kwak¹, Hong Koo Ha²

¹Deep Bio Inc. Seoul, Korea.

²Department of Urology and Biomedical Research Institute, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Korea.

PubMed PMC DOI PDF

Abstract

Artificial intelligence (AI) in digital pathology has gained attention owing to its potential in urological cancer diagnosis and management. This review highlights AI's applications and challenges in three major urological cancers. Prostate cancer studies have demonstrated reliable diagnostic performance and promising prognosis prediction. Renal cancer study shows potential but faces challenges in…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.